Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Citi Upgrades Ionis Pharmaceuticals (IONS) to Neutral
May 4, 2023 6:27 AM EDTCiti analyst David Lebowitz upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Sell to Neutral with a price target of $36.00 (from $30.00).
The analyst comments "Upgrading to Neutral, Raising PT to $36 (+$6) Eplontersen prospects in ATTR is a key driver for LT growth. Recently reported full data continues to suggest eplontersen is... More
